Showing 1401-1410 of 1676 results for "".
- AI Optics Receives FDA Clearance for Handheld Retinal Imaging Systemhttps://modernod.com/news/ai-optics-receives-fda-clearance-for-handheld-retinal-imaging-system/2482650/AI Optics has received FDA 510(k) clearance for its Sentinel Camera, a handheld retinal imaging system designed to capture high-quality images of the eye. Al Optics said the device helps to address critical gaps in retinal disease screening through a
- 4DMT Announces Phase 2 PRISM Interim Results for Intravitreal 4D-150 in Wet AMDhttps://modernod.com/news/4dmt-announces-phase-2-prism-interim-results-for-intravitreal-4d-150-in-wet-amd/2482364/4D Molecular Therapeutics announced initial interim 24-week landmark data from the population extension cohort of the PRISM phase 2 clinical trial, which evaluated intravitreal 4D-150 in a broad wet AMD patient population. The data were presented by Raj K. Maturi, MD, at the A
- CorNeat EverPatch Synthetic Tissue Substitute Now Available in the UShttps://modernod.com/news/corneat-everpatch-synthetic-tissue-substitute-now-available-in-the-us/2482138/CorNeat Vision announced the commerical launch of the CorNeat EverPatch, a synthetic tissue-integrating matrix for ocular surface surgeries. The EverPatch, which received FDA 510(k) clearance in June 2023, offers a combination of features that provide an advantage over ex
- IntRIS Hosts ARCR Macular 2024 Meeting and Presents Interview With FDA’s Dr. Wiley Chambershttps://modernod.com/news/intris-hosts-arcr-macular-2024-meeting-and-presents-interview-with-fdas-dr-wiley-chambers/2482057/The International Retinal Imaging Society (IntRIS) hosted the Atlantic Coast Retina Club (ACRC) Macula 2024, led by K. Bailey Freund, MD. According IntRIS, the ACRC meeting format includes rapid-fire single-case presentations, engaging discussions, and conferences covering diverse retin
- Belkin Vision Announces FDA Clearance for the Eagle for Selective Laser Trabeculoplastyhttps://modernod.com/news/belkin-vision-announces-fda-clearance-for-the-eagle-device/2482005/Belkin Vision has received FDA 510(k) clearance for the Eagle device, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser intended for use in performing selective laser trabeculoplasty (SLT). Belkin describes the Eagle as the first and only contactless l
- Ocuphire Pharma Names Joseph Schachle as COOhttps://modernod.com/news/ocuphire-pharma-names-joseph-schachle-as-coo/2481981/Ocuphire Pharma announced the appointment of Joseph (Joe) K. Schachle, MBA, into the newly created role of Chief Operating Officer, effective immediately. Ocuphire is a clinical-stage company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refra
- Lensar and Oertli Provide Update on Plans to Integrate Phaco Technology into the ALLY Adaptive Cataract Treatment Systemhttps://modernod.com/news/lensar-and-oertli-provide-update-on-plans-to-integrate-phaco-technology-into-the-ally-adaptive-cataract-treatment-system/2481923/Lensar said it is closer to its plans to integrate phacoemulsification technology from Oertli Instrumente into the ALLY Adaptive Cataract Treatment System. Oertli filed with the FDA a 510(k) for their Faros device, which if cleared, will bring Lensar a step closer to deliver comb
- Altris Receives FDA Clearance of Altris IMS Platform for OCT Scan Analysishttps://modernod.com/news/altris-receives-fda-clearance-of-altris-ims-platform-for-oct-scan-analysis/2481833/Altris received FDA 510(k) clearance for the Altris IMS, the company’s image, and data management platform. The Altris platform is designed to store, organize, and support in-depth analysis of Optical Coherence Tomography (OCT) scans. The platform provides secu
- Euclid Vision Issues Statement on the Passing of Co-Founder George Gladyhttps://modernod.com/news/euclid-vision-issues-statement-on-the-passing-of-co-founder-george-glady/2481771/Euclid Vision issued a statement memorializing George Glady, one of the company's founders who has passed away. Mr. Glady was a pioneer in Ortho-K, which has been an innovation used by millions of patients around the world to slow the progression of myopia. The state
- Harrow Acquires Santen’s Branded Ophthalmic Portfoliohttps://modernod.com/news/harrow-acquires-santens-branded-ophthalmic-portfolio/2481735/Harrow announced it is acquiring certain US and Canadian commercial rights to several branded ophthalmic products from Santen. According to an 8-K filing with the SEC, Harrow will make a one-time upfront payment of $8 million, with future near- and medium-term milestone